Led the creation and establishment of a five person data science and advanced analytics team in Lead Discovery and Optimization (LDO) within Small Molecule Drug Discovery (SMDD). Implementing novel ML tools, dashboards, and applications to boost drug discovery capabilities and reduce development timelines.● Developing next generation hit identification in high content screening assays utilizing convolutional neural networks and autoencoders● Establishing de novo phenotypic screening target deconvolution methods utilizing historic data mining, large language models (LLMs), and ‘omics integration with high throughput screening data● Secured $300k in funding and supervised the build of a full service AWS pipeline to enable image movement to sagemaker for model analysis● Established a cross-department initiative to build a sequential screening pipeline using classification models to identify high probability hits from subset libraries● Established 1 year collaboration with Matt Lazzara at University of Virginia to model assay variability in high throughput data and build next generation systems biology models

Established the Data Science and Advanced Analytics team within Leads Discovery and Optimization at Bristol Myers Squibb. Established foundational capabilities to ensure rapid scientific application implementation, coordinated a first-in-BMS AI competition, and developed several ML-based suites directly impact project deliverables.

• Team lead for automation engineers supporting lead profiling and lead evaluation biologics platforms• Developed an automation refresh plan for drug absorption assays Caco-2 and PAMPA, including cell culture and screening platforms – led planning, vendor coordination, FAT/SAT activities, and validation• Established an antibody functional profiling platform via a collaboration between core automation and scientific screening team• Established proof of concept applications of machine learning and real time image processing in process automation to enhance reliability and reduce user demand

• Developed biologics processes via data-intensive and statistical model-based approaches for rapid first-in-human timelines with presumptive critical quality attributes • Led a team 3 scientists and engineers for project deliverables and new technology initiatives• Led the strategy and implementation of high-throughput process development (HTPD) efforts including the development of scalable models for chromatography, solubility, and ultrafiltration• Contributed to the development of early phase biologic programs while building cross-functional collaborations with discovery and drug product scientists • Developed chromatography modeling and simulation tools to enable best-in-class prediction of bench-scale column performance from HTPD data• Process development point of contact for design of new laboratory space• Process development representative for outsourced baculovirus-infected insect cell based adeno-associated viral gene therapy program• Participated in rotation with antibody-drug conjugate program and successfully established proof of concept for on-column conjugation

• Led lab and pilot scale development activities for purification unit operations of a live virus vaccine in support of a new facility start-up in accordance with cGMP• Technical operations support for in-line live virus vaccine in accordance with cGMP• Improved robustness and increased process yield via development of models to optimize chromatography packing and operation• Led design of a new lab supporting downstream process development for viral vaccine manufacturing• Yellow-belt certification

• Scientific lead of lipid nanoparticle (LNP) discovery team with matrix responsibilities for scientists and engineers which contributed to a program-wide initiative to identify a lead vehicle composition• Led automation efforts for LNP formulation program; developed an automated system for high throughput formulation of LNPs; developed automated tangential flow filtration technologies• Applied chromatographic methods to separate LNPs via multiple modes (e.g., ion exchange, hydrophobic interaction, and size exclusion)• Streamlined systems for project management, data storage, and inventory control

• Developed a method to silence lysosomal DNase II via RNAi to probe nonviral gene transfer• Formatted and developed screens for a 16,000+ siRNA library of the human druggable genome• Performed siRNA library screen on nonviral, adenovirus, and adeno-associated viral vectors

Investigated dosing temperature and evacuation time on Vanadium Oxide supported catalysts using ultra-high vacuum and temperature-programmed desorption techniques.

Quantified protein adsorption on chromatographic particles via the measurement of adsorption isotherms.